^
Association details:
| Biomarker: | BRCA wild-type |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | carboplatin (Tubulin polymerization promoter) + paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse
Published date:
01/11/2023
Excerpt:
In BRCA wild type patients without maintenance, better progression-free survival occurred with carboplatin/paclitaxel (median progression-free survival 14.3 months) than with carboplatin/gemcitabine and carboplatin/pegylated liposomal doxorubicin (9.8 and 11.8 months, respectively; p=0.017)...treatment with carboplatin/paclitaxel appears to be more effective than carboplatin/gemcitabine and carboplatin/pegylated liposomal doxorubicin in BRCA wild type patients with high-grade serous ovarian cancers at first platinum-sensitive relapse.
DOI:
10.1136/ijgc-2022-003993
